Ambey Laboratories Ltd

As of 14-Nov, Ambey Laboratories Ltd is currently priced at 43.25, reflecting an 8.26% increase and strong short-term performance, outperforming the Sensex with a 1-week return of +12.05%. However, it has a year-to-date decline of -32.16%, indicating challenges over a longer period despite recent gains.

As of 12-Nov, Ambey Laboratories Ltd's stock price is declining at 36.95, down 4.15%, and underperforming its sector. The company faces significant challenges, with a year-to-date decline of 42.04%, contrasting sharply with the broader market's positive performance.

As of 03-Nov, Ambey Laboratories Ltd's stock price is at 39.00, down 2.62%, and has significantly underperformed its sector and the broader market, with a year-to-date decline of 38.82%. The stock is trading below all major moving averages, and investor participation has dropped notably, indicating ongoing challenges for the company.

As of 26-Sep, Ambey Laboratories Ltd's stock price is at 41.25, down 3.06% today and significantly down 35.29% year-to-date. Despite a recent increase in investor participation, the stock has underperformed compared to the broader market, which has gained 4.27% year-to-date.

As of 24-Sep, Ambey Laboratories Ltd is seeing a price increase to 44.35, up 3.62%, with strong performance and increased delivery volume indicating rising investor interest. Despite a year-to-date decline of 30.43%, recent gains suggest a potential recovery phase amidst a generally weak market.

As of September 23, 2025, Ambey Laborator is considered very expensive and overvalued with a PE Ratio of 21.92 and an EV to EBITDA of 15.02, significantly underperforming with a -39.55% return compared to the Sensex's -2.97%.

As of 23-Sep, Ambey Laboratories Ltd is currently priced at 42.80, reflecting a 2.88% increase, but has seen a year-to-date decline of 32.86%. Despite short-term gains, long-term performance is concerning with a 39.55% drop over the past year and declining investor participation.

As of 22-Sep, Ambey Laboratories Ltd's stock price is at 41.60, reflecting a 1.84% increase today and outperforming its sector. However, it remains down 34.75% year-to-date, indicating significant underperformance compared to the benchmark Sensex.

As of 18-Sep, Ambey Laboratories Ltd's stock price is 41.50, up 0.85%, but investor participation has declined significantly. Despite recent gains, the stock has underperformed year-to-date and over the past year compared to the benchmark Sensex.

As of September 17, 2025, Ambey Laborator is considered expensive and overvalued with a PE ratio of 21.48 and a year-to-date return of -35.45%, especially when compared to its peers like UPL and Dhanuka Agritech.

As of September 16, 2025, Ambey Laborator is considered very expensive and overvalued with a PE Ratio of 21.40, despite having a lower PE than peers like P I Industries and Bayer CropScience, while its year-to-date return of -32.94% starkly contrasts with the Sensex's gain of 6.74%.

As of 16-Sep, Ambey Laboratories Ltd is currently priced at 42.75, reflecting a 3.26% increase today, but it has declined 39.28% over the year. Despite a short-term recovery with a 4.27% gain in the past month, its long-term performance remains weak compared to the broader market.

As of September 15, 2025, Ambey Laborator is considered overvalued with a valuation grade of expensive, reflected by a PE Ratio of 22.10 and an EV to EBITDA of 15.11, while its stock has underperformed the Sensex with a 35.06% decline year-to-date.

As of 09-Sep, Ambey Laboratories Ltd is priced at 42.40 with no change, reflecting a 0.00% movement. The stock has shown mixed performance, declining 2.64% over the past week but gaining 9.84% over the month, indicating potential resilience despite a year-to-date decline of 33.49%.

As of 08-Sep, Ambey Laboratories Ltd's stock price is at 42.40, unchanged, and has underperformed its sector by 0.48%. Despite a recent monthly gain of 9.84%, its year-to-date performance is down 33.49%, indicating a negative overall trend compared to the broader market.

As of 05-Sep, Ambey Laboratories Ltd is priced at 42.40, showing a slight increase today but significant year-to-date and annual declines of 33.49% and 43.84%. Despite outperforming the Sensex in the short term, long-term performance raises concerns due to declining investor participation.

As of 04-Sep, Ambey Laboratories Ltd is priced at 42.35, down 0.94%, with a significant drop in investor participation. Despite a recent 5.48% gain over the week, the stock has declined 33.57% year-to-date and 44.17% over the past year, indicating mixed performance relative to the broader market.

As of 03-Sep, Ambey Laboratories Ltd is priced at 42.75, down 1.84%, and has underperformed its sector. Despite a recent increase in investor participation, the stock has declined significantly year-to-date and over the past year, contrasting with the broader market's better performance.

As of 02-Sep, Ambey Laboratories Ltd's stock price is at 43.55, reflecting a slight decline of 0.11%. Despite a recent weekly increase of 5.83%, the stock has a year-to-date loss of -31.69% and a one-year return of -41.66%, indicating significant underperformance compared to the benchmark Sensex.